Interleukin-2 in Association with Increasing Doses of Interferon-Gamma in Patients with Advanced Cancer
| Autor: | D. Baume, M. Resbeut, Patrice Viens, J. R. Delpero, Anne-Marie Stoppa, C. Bressac, Corinne Aubert, Didier Blaise, Marc Lopez, Dominique Maraninchi, Daniel Olive, Maud Brandely, R. Favre, Y. Ayme, D. Hans |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Male Interleukin 2 Cancer Research medicine.medical_specialty Adolescent Dose Immunology Gastroenterology Metastasis Interferon-gamma Renal cell carcinoma Neoplasms Internal medicine medicine Humans Immunologic Factors Immunology and Allergy Interferon gamma Pharmacology business.industry Melanoma Remission Induction Cancer Middle Aged medicine.disease Recombinant Proteins Surgery Lymphoma Drug Evaluation Interleukin-2 Female business medicine.drug |
| Zdroj: | Europe PubMed Central |
| ISSN: | 1524-9557 |
| DOI: | 10.1097/00002371-199204000-00009 |
| Popis: | Twenty-seven patients with evaluable metastatic cancer were treated with recombinant interleukin-2 (rIL-2) and escalating doses of interferon gamma (IFN-gamma). rIL-2 was infused over a 15 min period at a constant dose (8 x 10(6) IU/m2/8 h x 5 days first cycle, and 8 x 10(6) IU/m2/12 h x 5 days second and third cycles, with 9 days rest between each cycle). IFN-gamma was started 4 days before each cycle of rIL-2 and was given every other day at a dosage of 1 x 10(6) U/m2 x 3/cycle (four patients), 5 x 10(6) U/m2 x 3/cycle (four patients), 5 x 10(6) U/m2 x 5/cycle (four patients) and 10 x 10(6) U/m2 x 5/cycle (15 patients). Common side effects were fluid retention and hepatic toxicity (27 and 15% grade greater than or equal to 2); one ischemic chest pains and one acute respiratory distress occurred. Toxicities were not greater than those described with high dose rIL-2 alone and were similar in each dose level of IFN-gamma. No patient died from the procedure. Four patients responded, one complete response and three partial responses; all were treated with 25 or 50 x 10(6) U/m2/cycle of IFN-gamma (melanoma, two patients; renal cell carcinoma, one patient; lymphoma, one patient). Further phase II studies at these dosages are justified to precisely define the antitumoral efficacy of this association. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|